Peter Voorhees, MD

Dr Peter Voorhees outlines advice for community oncologists who treat patients with R/R multiple myeloma.

Dr Voorhees shares his perspective on bispecifics, ADCs, and CAR T-cell therapy in the treatment landscapes of R/R multiple myeloma.

Dr Peter Voorhees highlights MonumenTAL-1, discussing management of notable adverse events and health-related quality of life outcomes from patients with R/R multiple myeloma.

Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.

Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.

Considerations for future unmet needs and novel therapies in multiple myeloma, followed by practical advice for community oncologists.

In the context of multiple myeloma, Peter Voorhees, MD, considers the role of doublet vs triplet therapy, initial therapy selection, and monitoring treatment response.

Peter Voorhees, MD, reflects on practical implications of the MAIA trial and how best to manage a patient with newly diagnosed multiple myeloma.

Updated results from the MAIA trial, which tested the addition of daratumumab to lenalidomide-dexamethasone therapy in patients with transplant-ineligible newly diagnosed multiple myeloma.

Expert insight on the optimal management of transplant-ineligible newly diagnosed multiple myeloma in light of available therapies and clinical data.

Peter Voorhees, MD, provides a broad overview on risk assessment and the goals of therapy in multiple myeloma management.

Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.

Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.